NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
08 Feb 2017

Prexton Therapeutics Series B financing round raises EUR 29 million (USD 31 million) to advance its novel Parkinson’s therapeutic

Prexton Therapeutics (Prexton), today announces the closing of a Series B financing round of EUR 29 million (USD 31 million).
Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma<
06 Feb 2017

Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma

Landmark clinical trial has launched for rare disease with no approved targeted therapy.
31 Jan 2017

TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis

TiGenix NV today announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
23 Jan 2017

Sanifit Announces Enrollment of First Patient in CaLIPSO – a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Laboratoris Sanifit S.L., today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472.
18 Jan 2017

Minoryx Therapeutics further strengthens its scientific advisory board

Minoryx Therapeutics today announces that, Dr. Patrick Aubourg, Dr. Marc Engelen, Dr. Florian Eichler and Dr. Gerald Raymond, four renowned clinical experts in X-ALD joined its scientific advisory board.
17 Jan 2017

Aelix Therapeutics appoints industry expert Philippe Monteyne as independent board member

Aelix Therapeutics, has appointed Dr Philippe Monteyne as an independent member of its board of directors.
06 Jan 2017

Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

Kala Pharmaceuticals, Inc. announced today that Mark Iwicki, Chairman and Chief Executive Officer of Kala, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 11, 2017 at 4:00 PM PST.
20 Dec 2016

Takeda makes €10 million equity investment in TiGenix

TiGenix NV announced today that it has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix.
20 Dec 2016

TiGenix announces closing of NASDAQ IPO

TiGenix NV announced today the closing of its initial public offering in the United States totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS. 
15 Dec 2016

TiGenix raises $35.65 million gross proceeds with NASDAQ IPO

TiGenix NV announced today the pricing of its initial public offering in the United States (the "Offering") totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares ("ADSs"), representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS. 

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.